Adam Brufsky, MD, Oncology, Pittsburgh, PA, UPMC Presbyterian

AdamMBrufskyMD

Oncology Pittsburgh, PA

Hematologic Oncology

Professor of Medical Oncology, University Pittsburgh

Overview of Dr. Brufsky

Dr. Adam Brufsky is an oncologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including UPMC Presbyterian, UPMC Magee-Womens Hospital, and Shadyside Campus. He received his medical degree from University of Connecticut School of Medicine and has been in practice 27 years. Dr. Brufsky accepts several types of health insurance, listed below. He is one of 82 doctors at UPMC Magee-Womens Hospital and one of 144 doctors at UPMC Presbyterian who specialize in Oncology.

Education & Training

  • Dana-Farber Cancer InstituteFellowship, Medical Oncology, 1992 - 1995
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1992
  • University of Connecticut School of Medicine
    University of Connecticut School of MedicineClass of 1990

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2012 - 2022
  • PA State Medical License
    PA State Medical License 1996 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Pittsburgh Magazine Castle Connolly, 2005-2009
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A Metastatic Breast Cancer Patient with Activating HER2 Exon 20 Insertion Mutation Responds to Poziotinib; A Case Report of Compassionate Drug Use 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Results from APHINITY Trial Using BluePrint® as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
    Results from APHINITY Trial Using BluePrint® as a Biomarker Assay Presented at SABCS in Poster Spotlight DiscussionDecember 11, 2020 13:04
  • Monitoring Metastatic Breast Cancer Treatment Response: 5 Things to Know
    Monitoring Metastatic Breast Cancer Treatment Response: 5 Things to KnowDecember 08, 2020 12:12
  • Triple-Negative Breast Cancer: Expert Perspectives on Recent Advances
    Triple-Negative Breast Cancer: Expert Perspectives on Recent AdvancesOctober 24, 2020 18:58
  • Join now to see all

Grant Support

  • Safety Study Of Recombinant Monoclonal AntibodyNational Center For Research Resources1999–2002
  • Rhumabher2/Cyclophosphamide/Doxorubicin And Placebo/Cyclophosphamide/DoxorucinbNational Center For Research Resources1998–2002
  • Recombinant Humanized Anti-185her2 Monoclonal Antibody In Breast CancerNational Center For Research Resources1998–2002
  • Liposomal Annamycin In Taxane Resistant Breast CancerNational Center For Research Resources1999–2000
  • Androgen Receptor Associated Proteins In Prostate CancerNational Cancer Institute1996–1998
  • Androgen Receptor Associated Proteins In Prostate CancerNational Cancer Institute1995

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    BCBS Blue Card PPO
    BCBS Wyoming BlueChoice Personal
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Great West PPO
    HealthAmerica HealthAssurance PPO
    Highmark BCBS ClassicBlue
    Highmark BCBS PPOBlue
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment